Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 26, 2009

View Archived Issues

Array BioPharma discovers oncolytic checkpoint kinase inhibitors

Case control analysis reveals reduced AD risk with IV immunoglobulin

Enhanced fibrinolytic potency seen with reprogrammed streptokinases

Riluzole modulates alcohol self-administration and withdrawal in preclinical studies

Liraglutide safe and effective in combination with metformin and rosiglitazone

Astellas Pharma reports first quarter FY2009 results

Rifaximin accepted for filing and granted priority review by FDA

BrainStorm receives funding for ALS research trials

Nanotherapeutics awarded NIAID contract to develop inhaled smallpox antiviral

PharmaGap reports NCI results from GAP-107-B-8 testing

Regado enrolls first patient in phase I trial of anticoagulant REG1 System

R-Tech Ueno completes enrollment in phase II UF-021 study

Phase III Urocidin trial cleared to continue by DMC

Loramyc marketing authorization granted in Switzerland

Wyeth to continue liver X receptor target program initiated by Karo Bio

T-type calcium channel antagonist TTA-A8 a clinical candidate for sleep disorders

Preclinical characteristics of antidiabetic candidate canagliflozin described

GSK presents preclinical data on novel S1P1 agonist, PPI-4955, at recent ACS meeting

Shire designs prodrugs of mu opioid receptor ligands for pain treatment

Monoamine neurotransmitter reuptake inhibitors described by NeuroSearch

Bayer Schering Pharma identifies novel compounds acting on Toll-like receptors

Wisconsin Alumni Research Foundation describes VDR ligands for skin conditions

Bayer Schering Pharma claims novel MR antagonists, PR and AR agonists

Enrollment in phase IIa trial of ALV-003 for celiac disease started

Gene-based medicine for refractory angina enters phase I/IIa clinical development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...